Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease.
Tiselius
H G
HG
Department of Urology, Huddinge University Hospital, Stockholm, Sweden. hans-goran.tiselius@urol.hs.sll.se
D000493:Allopurinol / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000008:administration & dosage; D002129:Calcium Oxalate / Q000378:metabolism; D002136:Calcium, Dietary / Q000008:administration & dosage; D019343:Citric Acid / Q000008:administration & dosage; D004043:Dietary Fiber / Q000008:administration & dosage; D004044:Dietary Proteins / Q000008:administration & dosage; D004326:Drinking; D006025:Glycosaminoglycans / Q000627:therapeutic use; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage; D010349:Patient Compliance; D010710:Phosphates / Q000627:therapeutic use; D012008:Recurrence; D013844:Thiazoles / Q000627:therapeutic use; D014545:Urinary Calculi / Q000737:chemistry / Q000378:metabolism / Q000517:prevention & control*
D000963:Antimetabolites; D002136:Calcium, Dietary; D004043:Dietary Fiber; D004044:Dietary Proteins; D006025:Glycosaminoglycans; D010710:Phosphates; D013844:Thiazoles; D002129:Calcium Oxalate; D019343:Citric Acid; D000493:Allopurinol; D008274:Magnesium; D001205:Ascorbic Acid